

Trobix Bio Receives Patent Allowance in the USA

Netanya, Israel, May 25, 2022

Netanya, Israel. Trobix Innovation Ltd. ([Trobix Bio](#)), an Israeli-based biotechnology company developing precision microbiome-based life-changing therapies, announces that it has received from the United States Patent and Trademark Office (USPTO) a Notice of Allowance for its licensed US patent application 16/312,538 titled “Bacteriophage variants having extended host-range, methods for preparation and uses thereof in transducing nucleic acids into hosts of interest”. The allowed patent application covers the preparation of improved DNA delivery vehicles, specifically, engineered phages, having an extended host recognition ability. The patent further protects methods for manipulating a population of cells and therapeutic methods using the engineered bacteriophages of the invention

“We are excited to receive a USA patent allowance for this key patent family”, said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. “This follows approval of our first licensed patent, and the claims granted by the USPTO provide Trobix Bio with broad-based protection in the US, an important target market”, he added.

About Trobix Bio

Trobix Bio is empowering its TBX™ platform technology of engineered phages and CRISPR to develop life changing therapeutics. The company’s technology enables manipulating specific activities in the human microbiota for developing precision medicine therapeutics with a lasting and continuous effect. Trobix Bio has powerful in-house capabilities bio-converging computational, synthetic, and experimental biology, and is advancing the development of a diversified pipeline of precision medicine therapeutic products.

For more information, please contact:

Dr. Adi Elkeles

CEO & co-Founder

Trobix Bio

Tel: +972-54-6402333

Email: adie@trobixbio.com